Rho-kinase inhibitors

Handbook of Experimental Pharmacology

Volumn 218, Issue , 2013, Pages 351-363

  Fukumoto, Yoshihiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Pulmonary arterial hyperconstriction; Pulmonary arterial hypertension; Pulmonary arteriopathy; Rho kinase

Indexed keywords

AZAINDOLE 1; BERAPROST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CYTOKINESIS; CYTOSKELETON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84893029598     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-38664-0-14     Document Type: Article

References (51)

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94:385-393
2. Abe K, Morikawa K, Hizume T, Uwatoku T, Oi K, Seto M, Ikegaki I, Asano T, Kaibuchi K, Shimokawa H (2005) Prostacyclin does not inhibit Rho-kinase: An implication for the treatment of pulmonary hypertension. J Cardiovasc Pharmacol 45:120-124
3. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H (2006) Long-term inhibition of rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 48:280-285
4. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K (1997) Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 275:1308-1311
5. Dahal BK, Kosanovic D, Pamarthi PK, Sydykov A, Lai YJ, Kast R, Schirok H, Stasch JP, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Schermuly RT (2010) Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 36:808-818
6. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H (2009) Evidence for rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 73:1731-1739
7. Dorfmuller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358-363
8. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H (2010) Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25:144-149
9. Fukata Y, Amano M, Kaibuchi K (2001) Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 22:32-39
10. Fukumoto Y, Shimokawa H (2011) Recent progress in the management of pulmonary hypertension. Circ J 75:1801-1810
11. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H (2005) Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391-392
12. Fukumoto Y, Tawara S, Shimokawa H (2007) Recent progress in the treatment of pulmonary arterial hypertension: Expectation for Rho-kinase inhibitors. Tohoku J Exp Med 211:309-320
13. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, Kihara Y, Kawano M, Watanabe H, Takeda Y, Adachi T, Osanai S, Tanabe N, Inoue T, Nakano T, Shimokawa H (2013) A double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension; a pilot efficacy trial. http://dx.doi.org/10.1253/circj.CJ-13-0443. Circ J 77:2691-2625
14. Giaid A, Saleh D (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333:214-221
15. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res 93:767-775
16. Higenbottam TW, Laude EA (1998) Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles f. Filley lecture. Chest 114:72S-79S
17. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A (2004) Inflammatory stimuli upregulate rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 37:537-546
18. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, RabinovitchM(2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S
19. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T (2006) Beneficial acute effects of Rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70:174-178
20. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15:1885-1893
21. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H (2007) Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 49:85-89
22. Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, Lenz J, Franz JK, Knorr A, Hutter J, Lobell M, Zimmermann K, Munter K, Augstein KH, Ehmke H, Stasch JP (2007) Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol 152:1070-1080
23. Leung T, Manser E, Tan L, Lim L (1995) A novel serine/threonine kinase binding the Ras-related Rhoa GPTase which translocates the kinase to peripheral membranes. J Biol Chem 270:29051-29054
24. Liao JK, Seto M, Noma K (2007) Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50:17-24
25. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, Schaefer M, Linz W, Kohlmann M, Herbert JM, Janiak P, O'Connor SE, Ruetten H (2009) Pharmacological characterization of sar407899, a novel Rho-kinase inhibitor. Hypertension 54:676-683
26. Loirand G, Guerin P, Pacaud P (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98:322-334
27. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A (2001) Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38:1307-1310
28. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A (2002) Suppression of coronary artery spasm by the rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547
29. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417-1431
30. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A (2003) Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 41:15-19
31. Morishige K, Shimokawa H, Eto Y, Kandabashi T, Miyata K, Matsumoto Y, Hoshijima M, Kaibuchi K, Takeshita A (2001) Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 21:548-554
32. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171:494-499
33. Narumiya S (1996) The small GTPase Rho: Cellular functions and signal transduction. J Biochem 120:215-228
34. Oka M, Fagan KA, Jones PL, McMurtry IF (2008) Therapeutic potential of Rhoa/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 155:444-454
35. Pankey EA, Byun RJ, Smith WB 2nd, Bhartiya M, Bueno FR, Badejo AM, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ (2012) The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat. Can J Physiol Pharmacol 90:825-835
36. Peng G, Ivanovska J, Kantores C, Van Vliet T, Engelberts D, Kavanagh BP, Enomoto M, Belik J, Jain A, McNamara PJ, Jankov RP (2012) Sustained therapeutic hypercapnia attenuates pulmonary arterial Rho-kinase activity and ameliorates chronic hypoxic pulmonary hypertension in juvenile rats. Am J Physiol Heart Circ Physiol 302:H2599-H2611
37. Shimokawa H (2000) Cellular and molecular mechanisms of coronary artery spasm: Lessons from animal models. Jpn Circ J 64:1-12
38. Shimokawa H (2002) Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39:319-327
39. Shimokawa H, Rashid M (2007a) Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 28:296-302
40. Shimokawa H, Rashid M (2007b) Rho-kinase inhibitors for cardiovascular medicine. Its rationale and current status. Trends Pharmacol Sci 28:296-302
41. Shimokawa H, Takeshita A (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25:1767-1775
42. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A (1999) Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43:1029-1039
43. Somlyo AP, Somlyo AV (2000) Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522(Pt 2):177-185
44. Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208
45. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK (2002) Rho-kinase mediates hypoxiainduced downregulation of endothelial nitric oxide synthase. Circulation 106:57-62
46. Tawara S, Fukumoto Y, Shimokawa H (2007) Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 50:195-200
47. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990-994
48. Williams RD, Novack GD, van Haarlem T, Kopczynski C (2011) Ocular hypotensive effect of the rho kinase inhibitor ar-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol 152:834-841
49. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC (2004) Increased arginase II and decreased no synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18:1746-1748
50. Yasuda T, Tada Y, Tanabe N, Tatsumi K, West J (2011) Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 301:L667-L674
51. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr, Gaine SP, Orens JB, Rubin LJ (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98:1400-1406